2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-101140A
    KI696 isomer 1799974-69-8 98.44%
    KI696 isomer is the less active isomer of KI696 (HY-101140). KI696 is a high affinity probe that disrupts the Keap1/NRF2 interaction.
    KI696 isomer
  • HY-108036A
    (S)-Pro-xylane 868156-46-1 99.72%
    (S)-Pro-xylane ((S)-Hydroxypropyl tetrahydropyrantriol) is a bioactive C-glycoside that targets the biosynthesis pathway of glycosaminoglycans/mucopolysaccharides (GAGs) in the skin matrix and can be absorbed transdermally. (S)-Pro-xylane stimulates the biosynthesis of GAGs in fibroblasts, enhances the structural stability of the skin extracellular matrix, improves skin elasticity and moisturizing ability, and delays wrinkle formation. (S)-Pro-xylane can effectively promote the synthesis of collagen fibers and hyaluronic acid in the dermis. (S)-Pro-xylane is used in the field of anti-aging cosmetics to improve skin hydration and elasticity. (S)-Pro-xylane is eco-friendly and biodegradable.
    (S)-Pro-xylane
  • HY-113511B
    Glycogen, from rabbit liver, ≥85% 9005-79-2
    Glycogen, from rabbit liver, ≥85% is glycogen extracted from rabbit liver. Glycogen, from rabbit liver, ≥85% is a branched polysaccharide condensed from glucose and serves as a storage form of glucose in the body. Glycogen, from rabbit liver, ≥85% plays an important role in physiological processes such as maintaining blood sugar and providing energy.
    Glycogen, from rabbit liver, ≥85%
  • HY-153497A
    Vupanorsen sodium 2172852-12-7 98.33%
    Vupanorsen (sodium) is an N-acetyl galactosamine-conjugated antisense oligonucleotide that inhibits Angiopoietin-like 3 (ANGPTL3) protein synthesis. Vupanorsen (sodium) lowers triglycerides and atherogenic lipoproteins.
    Vupanorsen sodium
  • HY-N0830S4
    Palmitic acid-d2 62689-96-7 99.8%
    Palmitic acid-d2 is the deuterium labeled Palmitic acid. Palmitic acid is a long-chain saturated fatty acid commonly found in both animals and plants. Palmitic acid can induce the expression of glucose-regulated protein 78 (GRP78) and CCAAT/enhancer binding protein homologous protein (CHOP) in in mouse granulosa cells.
    Palmitic acid-d2
  • HY-P11321A
    IUB0271 hydrochloride 98.67%
    IUB0271 (acyl-GIP) hydrochloride is a fatty acylated and long-acting glucose-dependent insulinotropic polypeptide (GIP). IUB0271 hydrochloride increases cFos neuronal activity in hypothalamic feeding centers and decreases body weight, food intake and glycemia in DIO mouse models, and these effects depend on CNS-GIPR signaling. IUB0271 hydrochloride can be used for type 2 diabetes mellitus (T2DM) and obesity research.
    IUB0271 hydrochloride
  • HY-W007319
    Phenylpropiolic acid 637-44-5
    Phenylpropiolic acid is an endogenous metabolite. Phenylpropiolic acid is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Phenylpropiolic acid
  • HY-W007539
    2,4-Dihydroxybenzaldehyde 95-01-2 99.93%
    2,4-Dihydroxybenzaldehyde is an endogenous metabolite. 2,4-Dihydroxybenzaldehyde is a pharmaceutical intermediate that can be used to synthesize various Schiff base compounds. 2,4-Dihydroxybenzaldehyde exhibits significant anti angiogenic, anti-inflammatory, and analgesic activities. 2,4-Dihydroxybenzaldehyde reduces the production of NO and ROS by inhibiting the expression of iNOS and COX-2. 2,4-Dihydroxybenzaldehyde is commonly used in the study of inflammatory conditions.
    2,4-Dihydroxybenzaldehyde
  • HY-W009417
    Cedryl acetate 77-54-3 99.43%
    Cedryl acetate is an orally active α-glucosidase inhibitor with an IC50 of 94 μM against yeast α-glucosidase. Cedryl acetate reduces high-fat diet-induced body weight gain, visceral fat pad weight, adipocyte hypertrophy, hepatic lipid accumulation, glucose intolerance, insulin resistance and gluconeogenesis. Cedryl acetate can be used in the research of obesity and obesity-related metabolic syndrome.
    Cedryl acetate
  • HY-W012658
    2-Methylacetophenone 577-16-2 99.60%
    2-Methylacetophenone (O-Methylacetophenone), acetophenone derivative and acaricide, is a xanthine dehydrogenase (XDH) inhibitor. 2-Methylacetophenone competitively binds to the XDH active site, blocking the pathway for xanthine to be converted to uric acid. 2-Methylacetophenone can be used for the study of hyperuricemia and house dust.
    2-Methylacetophenone
  • HY-W013061
    Propane-1,2,3-triyl tripalmitate 555-44-2 99.63%
    Propane-1,2,3-triyl tripalmitate is a saturated fat. Propane-1,2,3-triyl tripalmitate enhances the lymphatic transport of Glycerol tristearate (HY-127035).
    Propane-1,2,3-triyl tripalmitate
  • HY-W014839
    Cyclamic acid sodium 139-05-9 98.0%
    Cyclamic acid sodium (Sodium cyclamate) is a commonly used sweetener. Cyclamic acid sodium is toxic to osteoblasts and can inhibit cell proliferation, induce apoptosis and reduce cell mineralization. Cyclamic acid sodium causes focal necrosis of bladder organs in rats in vitro, which can promote bladder cancer, but some studies have shown that low doses of Cyclamic acid sodium have no carcinogenic effect. In addition, Cyclamic acid sodium has no effect on insulin and glucagon secretion induced by arginine.
    Cyclamic acid sodium
  • HY-W018171
    3,5,6-Trichloro-2-pyridinol 6515-38-4 99.85%
    3,5,6-Trichloro-2-pyridinol (TCPy) is a chloride of 2-pyridone with oral activity. 3,5,6-Trichloro-2-pyridinol is the main degradation product of the herbicide Triclopyr and the insecticides Chlorpyrifos and chlorpyrifos-methyl. 3,5,6-Trichloro-2-pyridinol is associated with attention deficit hyperactivity disorder (ADHD) and decreased testosterone levels. 3,5,6-Trichloro-2-pyridinol causes hearing loss, hepatotoxicity and nephrotoxicity in mice .
    3,5,6-Trichloro-2-pyridinol
  • HY-W039898
    α-D-Mannose pentaacetate 4163-65-9
    α-D-Mannose pentaacetate (1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose) acts as a lactate promoter. It increases lactate production in rat red blood cells.
    α-D-Mannose pentaacetate
  • HY-W004284S1
    Heptadecanoic acid-d33 352431-41-5 99.88%
    Heptadecanoic acid-d33 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
    Heptadecanoic acid-d33
  • HY-16086
    Balaglitazone 199113-98-9 99.25%
    Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
    Balaglitazone
  • HY-28247
    N-Formylkynurenine 1022-31-7 98.88%
    N-Formylkynurenine is an intermediate in the catabolism of tryptophan. It is a formylated derivative of kynurenine. The formation of N-formylkynurenine is catalyzed by heme dioxygenases.
    N-Formylkynurenine
  • HY-B0380
    Trimebutine 39133-31-8 99.42%
    Trimebutine is a multi-target inhibitor and opioid receptor agonist with antimuscarinic activity. Trimebutine inhibits L-type Ca2+ channels and large-conductance calcium-activated potassium channels (BKCa channels), thereby inhibiting extracellular calcium influx and potassium ion efflux. Trimebutine also targets Toll-like receptors, inhibits Toll-like receptor 2/4/7/8/9 signals, and inhibits LPS-induced IRAK1 activation, as well as ERK1/2, JNK and NF-κB activation, thereby exerting anti-inflammatory effects. Trimebutine also induces tumor cell apoptosis by inhibiting the AKT/ERK pathway. Trimebutine also inhibits excessive contraction of smooth muscle and can be used in the study of gastrointestinal disorders such as irritable bowel syndrome (IBS).
    Trimebutine
  • HY-B1588
    Carbenoxolone 5697-56-3 99.9%
    Carbenoxolone is a blood-brain barrier-permeable Pannexin1 inhibitor, gap junction (Gap junction) blocker, and β-amyloid 42 inhibitor. Carbenoxolone modulates voltage-gated currents of wild-type and mutant Panx1, and inhibits stimulus-activated Panx1 channel function. Carbenoxolone interacts with stable residues of β-amyloid 42 peptides, fibrils and oligomers, thereby inhibiting their aggregation. Carbenoxolone alleviates liver fibrosis. Carbenoxolone exerts neuroprotective and nootropic effects. Carbenoxolone can be used in studies related to Alzheimer's disease and liver fibrosis.
    Carbenoxolone
  • HY-113270
    Actinine 407-64-7 99.90%
    Actinine is a metabolic and pro-atherogenic intermediate with oral activity. Actinine acts as a substrate for the yeaW/X microbial enzyme complex to generate trimethylamine (TMA). Actinine accelerates atherosclerosis development in a gut microbe-dependent manner. Actinine can be used for the research of atherosclerosis.
    Actinine
Cat. No. Product Name / Synonyms Application Reactivity